PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of actadInternational Union of Crystallographysearchsubscribearticle submissionjournal home pagethis article
 
Acta Crystallogr D Biol Crystallogr. Aug 1, 2010; 66(Pt 8): 881–888.
Published online Jul 9, 2010. doi:  10.1107/S0907444910020081
PMCID: PMC2917274
Structure of Staphylococcus aureus adenylo­succinate lyase (PurB) and assessment of its potential as a target for structure-based inhibitor discovery
Paul K. Fyfe,a Alice Dawson,a Marie-Theres Hutchison,a Scott Cameron,a and William N. Huntera*
aDivision of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland
Correspondence e-mail: w.n.hunter/at/dundee.ac.uk
Received March 8, 2010; Accepted May 27, 2010.
The medium-resolution structure of adenylosuccinate lyase (PurB) from the bacterial pathogen Staphylococcus aureus in complex with AMP is presented. Oxalate, which is likely to be an artifact of crystallization, has been modelled in the active site and occupies a position close to that where succinate is observed in orthologous structures. PurB catalyzes reactions that support the provision of purines and the control of AMP/fumarate levels. As such, the enzyme is predicted to be essential for the survival of S. aureus and to be a potential therapeutic target. Comparisons of this pathogen PurB with the enzyme from Escherichia coli are presented to allow discussion concerning the enzyme mechanism. Comparisons with human PurB suggest that the close similarity of the active sites would make it difficult to identify species-specific inhibitors for this enyme. However, there are differences in the way that the subunits are assembled into dimers. The distinct subunit–subunit interfaces may provide a potential area to target by exploiting the observation that creation of the enzyme active site is dependent on oligomerization.
Keywords: adenylosuccinate lyase, AMP, oxalate, purine biosynthesis, purine cycle
The purine-biosynthetic pathway is ultimately responsible for the generation of inosine 5′-monophosphate from α-d-ribose-5-phosphate (Zhang et al., 2008 [triangle]) and provides the essential purine nucleotides required for DNA replication and cell division. The pathway consists of ten enzyme-catalyzed steps in vertebrates (Buchanan & Hartman, 1959 [triangle]) and 11 in Escherichia coli (Mueller et al., 1994 [triangle]). In this pathway, adenylosuccinate lyase (PurB; EC 4.3.2.2) catalyzes the breakdown of 5-aminoimidazole-4-(N-succinylcarboxamide) ribotide (SAICAR) to 5-aminoimidazole-4-carboxamide ribotide (AICAR) and fumarate (Fig. 1 [triangle]). PurB demonstrates dual substrate specificity and can also break down adenylo­succinate to adenosine monophosphate (AMP) and fumarate (Fig. 1 [triangle]); therefore, it also determines the levels of AMP and fumarate in the cell via the purine-nucleotide cycle. In humans, mutations in PurB and adenylosuccinate lyase deficiency have profound effects on the central nervous system (Spiegel et al., 2006 [triangle]). It has been predicted on the basis of bioinformatics comparisons and metabolic reconstructions that the purB gene encodes an essential enzyme activity in Staphylococcus aureus (Heinemann et al., 2005 [triangle]), although we note that it would be important to genetically and chemically validate this prediction. Selective inhibition of PurB offers the possibility of new therapies targeting a range of microbial infections and structural studies provide useful data to assess the potential of this protein for such early stage drug discovery (Hunter, 2009 [triangle]).
Figure 1
Figure 1
PurB catalyzes two reactions: the conversion of SAICAR to AICAR (a) and the conversion of adenylosuccinate to AMP (b). In each case fumarate is also produced.
PurB is classified along with arginosuccinate lyase, l-­aspartase, class II fumarases and 3-carboxymuconate lactonase as a member of the aspartase/fumarase or β-elimination superfamily of enzymes (Fujii et al., 2003 [triangle]). Crystal structures of PurB from a number of organisms have been determined. These include orthologues from the archaea Pyrobaculum aerophilum (Toth et al., 2000 [triangle]) and Thermotoga maritima (Toth & Yeates, 2000 [triangle]), the eukaryotes Caenorhabditis elegans (PDB code 1yis; J. Symersky et al., unpublished work), Homo sapiens (PDB code 2vd6; P. Stenmark et al., unpublished work) and Plasmodium vivax (PDB code 2qga; Vedadi et al., 2007 [triangle]) and the bacteria E. coli (Tsai et al., 2007 [triangle]), Bacillus anthracis (PDB code 2pfm; V. M. Levdikov, E. V. Blagova, A. J. Wilkinson & K. S. Wilson, unpublished work), B. subtilis (Toth et al., 2000 [triangle]) and Legionella pneumophila (PDB code 3bhg; C. Chang, H. Li, L. Freeman & A. Joachimiak, unpublished work).
We describe the construction of an efficient bacterial recombinant expression system, enzyme purification and crystallization protocols and report the crystal structure of PurB from S. aureus (SaPurB) at 2.5 Å resolution. Our structure contains one of the reaction products, AMP, bound in the active site and a nearby strong feature of electron density has been modelled and successfully refined as oxalate. Comparisons with previously determined PurB structures are presented, concentrating on active-site ligand interactions and the mode of dimerization.
2.1. Cloning and sample preparation
The S. aureus purB gene was amplified from genomic DNA (American Type Culture Collection strain 35556, Laboratory of the Government Chemist Standards Office, UK) using the primers 5′-catatgATTGAACGCTATTCTCGAG and 5′-ctc­gagTTATGCTAATCCAGCGCG (the lower-case sequences correspond to the NdeI/XhoI restriction sites used for cloning). Following TOPO cloning (Invitrogen) of the PCR product, the gene was ligated into a pET15b (Novagen) expression vector modified to encode a tobacco etch virus (TEV) protease cleavage site in place of the thrombin protease cleavage site. This vector was transformed into E. coli BL21 (DE3) pLysS (Stratagene). Cultures were grown at room temperature in Luria–Bertani medium supplemented with 50 mg ml−1 ampicillin and 12 mg ml−1 chloramphenicol overnight, with 0.5 mM isopropyl β-d-1-thiogalactopyranoside added to induce gene expression, and the cells were harvested by centrifugation (3000g at 277 K for 30 min). The pellet was resuspended in 50 mM Tris–HCl pH 7.5, 250 mM NaCl, 20 mM imidazole and the cells were lysed using a French press. Cell debris was removed by centrifugation (40 000g at 277 K for 30 min).
SaPurB was purified with a protocol commonly used in our laboratory (Dawson et al., 2008 [triangle]). In summary, the first stage involved nickel-affinity chromatography on a 5 ml HisTrap column (GE Healthcare). A linear concentration gradient was applied to elute the product, which was dialyzed against 50 mM Tris–HCl, 250 mM NaCl; the His tag was then removed by incubation overnight with His-tagged TEV protease. The resulting mixture was applied onto the HisTrap column, which bound the cleaved His tag, the TEV protease and uncleaved SaPurB. The SaPurB from which the His tag had been cleaved was present in the flowthrough. Fractions were analyzed using SDS–PAGE and those containing SaPurB were pooled. The protein was further purified by size-exclusion chromatography using a Superdex 200 26/60 column (GE Healthcare) equilibrated with 50 mM Tris–HCl, 250 mM NaCl pH 7.5. This column had previously been calibrated with molecular-weight standards: blue dextran (>2000 kDa), thyro­globulin (669 kDa), ferritin (440 kDa), aldolase (158 kDa), conalbumin (75 kDa), ovalbumin (43 kDa), carbonic anhydrase (29.5 kDa), ribonuclease A (13.7 kDa) and aprotinin (6.5 kDa) (GE Healthcare; data not shown). The high level of SaPurB purity was confirmed by SDS–PAGE and matrix-assisted laser desorption/ionization–time-of-flight mass spectrometry. The sample was dialyzed into 20 mM Tris–HCl pH 7.5, 50 mM NaCl and concentrated using a Vivaspin 20 (Sartorius) to provide a stock solution for crystallization. A theoretical extinction coefficient of 59 485 M −1 cm−1 at 280 nm was used to estimate the protein concentration (PROTPARAM; Gasteiger et al., 2005 [triangle]); the theoretical mass of one subunit was estimated as 49.6 kDa.
SaPurB was crystallized at 293 K by the hanging-drop vapour-diffusion method using 1 µl protein solution at a concentration of 11 mg ml−1 containing 25 mM AMP mixed with 1 µl reservoir consisting of 45% polyethylene glycol (PEG) 200, 0.2 M NaCl and 0.1 M sodium phosphate buffer pH 6.2. Orthorhombic blocks with minimum dimensions of 0.2 mm grew over 2–3 weeks. Crystals were first characterized in-house using a Rigaku MicroMax-007 rotating-anode X-ray generator coupled to an R-AXIS IV++ image-plate detector. The amount of PEG 200 in the mother liquor allowed crystals to be mounted directly from the drop without additional cryoprotection. Autoindexing revealed that the crystals were ortho­rhombic, with unit-cell lengths that were subsequently determined as a = 81.6, b = 121.3, c = 105.7 Å. Suitable crystals were stored in liquid N2 for use in data collection at the Diamond Light Source (Rutherford Appleton Laboratories, England).
2.2. X-ray data collection, processing, structure solution and refinement
Diffraction data were measured on beamline I04 of the Diamond Light Source using an ADSC Q315 CCD detector. Data were indexed and integrated using MOSFLM (Leslie, 2006 [triangle]) and scaled using SCALA (Evans, 2006 [triangle]); statistics are summarized in Table 1 [triangle]. The structure was solved by molecular replacement using the structure of adenylosuccinate lyase from T. maritima (PDB code 1c3c; Toth & Yeates, 2000 [triangle]) as the search model. This model shares approximately 50% sequence identity to SaPurB. One molecule was located per asymmetric unit, giving a Z score of 21.1 using the program Phaser (McCoy et al., 2007 [triangle]). Refinement was performed in REFMAC5 (Murshudov et al., 1999 [triangle]) utilizing translation/libration/screw refinement and alternated with inspection of Fourier syntheses (2F oF c and F oF c) and model manipulation together with ligand incorporation using Coot (Emsley & Cowtan, 2004 [triangle]). MolProbity (Chen et al., 2010 [triangle]) was used to investigate model geometry in combination with the validation tools provided in Coot. Crystallographic statistics are presented in Table 1 [triangle]. Analyses of surface areas and inter­actions were made using the PISA service (Krissinel & Henrick, 2007 [triangle]) and figures were prepared with PyMOL (DeLano, 2002 [triangle]). Amino-acid sequence alignments were carried out using the program MUSCLE (Edgar, 2004 [triangle]). The coordinates and structure-factor data have been deposited in the Protein Data Bank with accession code 2x75.
Table 1
Table 1
Crystallographic statistics
3.1. General comments
SaPurB crystallizes in an orthorhombic system and the systematic absences indicated either space group I222 or I212121. Both space groups have eight asymmetric units per unit cell and a single polypeptide chain, labelled chain A, constitutes the asymmetric unit, with an estimated solvent content of 60%. The space-group assignment of I222 was confirmed using default settings in the program Phaser (McCoy et al., 2007 [triangle]) and the structure was solved by molecular replacement and refined to a resolution of 2.50 Å. The log-likelihood gain score in I222 was 742, compared with a score of 86 in I212121. As will be described, SaPurB forms a tetramer in the crystal structure and this rules out space group I212121. The crystallographic statistics and model geometry (Table 1 [triangle]) indicate that the analysis has produced an acceptable medium-resolution model. Continuous and well defined electron density was observed for the entire polypeptide except for residues 401 and 402. AMP, a product of the catalyzed reaction, was present in the crystallization conditions and well defined electron density for the ligand was observed in the active site (data not shown). Electron density compatible with PEG was located near the C-terminal segment of α7 and the C-terminal segment of α5 from a symmetry-related subunit (symmetry operation −x + 1/2, −y + 1/2, −z + 1/2, data not shown). In addition, a strong electron-density feature appeared in the active site which we could not explain on the basis of the known chemical components of the crystallization mixture. Different molecules were considered and refinements attempted. Our tentative interpretation is that this density represents oxalate (Fig. 2 [triangle]), possibly acquired as a contaminant of the PEG 200 used in crystallization. Contamination of PEG and its influence on protein crystallization has been observed previously (Jurnak, 1986 [triangle]). In our case, since ethylene glycol is a precursor of PEG and like PEG itself is susceptible to contamination with aldehydes and peroxides (Ray & Puvathingal, 1985 [triangle]), then breakdown of PEG 200 and/or the presence of ethylene glycol and subsequent oxidation may have produced oxalate.
Figure 2
Figure 2
Stereoview of the OMIT map of oxalate and interactions in the active site. The OMIT F oF c difference density map is shown as green chicken wire and contoured at 3σ. The protein main chain is shown (more ...)
3.2. Structure overview
The SaPurB subunit can be divided into three domains that combine to form an elongated structure. Domains I and III are placed at either end of the long helical bundle formed by domain II (Fig. 3 [triangle]). Domain I comprises residues 1–93, which form six helices (α1–α6). Domain II, consisting of residues 94–349, forms an elongated helical bundle assembled by α7 through α15 as well as a short two-stranded antiparallel β-­sheet (β1, β2) positioned between α7 and α8. Domain III comprises five helices (α16–α20) constructed from residues 350–431. This domain carries the only unresolved portion of the structure: residues 401 and 402 that are on a loop linking α18 with α19 are disordered.
Figure 3
Figure 3
Ribbon diagrams of the SaPurB subunit, the dimer and the tetramer. (a) A subunit is depicted and coloured from the N-terminus (blue) to the C-­terminus (red). Residues of the subunit interact with three AMP molecules, which are shown in CPK format (more ...)
Gel filtration indicates that SaPurB exists as a single species with an approximate mass of 85 kDa in solution, suggesting the presence of a dimer under the conditions used during the final stage of purification. In the crystal structure, a symmetry-related subunit (B) related by the crystallographic twofold axis along unit-cell edge a is the likely partner for such a dimeric species. The AB interface covers an area of approximately 3380 Å2; almost 16% of the total surface area of the subunit. As observed in orthologues, the crystal structure reveals the formation of a tetramer (Fig. 3 [triangle]), which in the case of SaPurB involves rotation of the AB pair about the crystallographic axis along unit-cell edge b to provide the partner pair of subunits, which are labelled C and D. The AC interface extends for approximately 1750 Å2 or 8% of the surface area of a subunit, whilst the smallest interface, that formed between subunits A and D, covers an area of about 1600 Å2 or 7.5% of the subunit surface area. Changes in the multimeric state of PurB orthologues have been reported elsewhere. The B. subtilis enzyme has been shown to exist largely as a dimeric species when the protein concentration is low (~0.1 mg ml−1); however, as the protein concentration increases the tetrameric species becomes the most abundant form (Palenchar & Colman, 2003 [triangle]).
3.3. The active site, interactions with ligands and enzyme mechanism
The tetramer contains four active sites, each formed by regions donated from three different subunits. In the following description, AB or C after the residue numbers serves to identify which subunit they belong to. We consider distances between functional groups involved in hydrogen-bonding interactions to fall within the range 2.5–3.5 Å.
A sequence alignment of PurB proteins for which structures have been determined was carried out and a subset is presented in Fig. 4 [triangle] together with the secondary structure of SaPurB. The PurB sequences of T. maritima and B. anthracis share 52 and 70% identity, respectively, to that of SaPurB. The remainder, L. pneumophila, E. coli, Pl. vivax, C. elegans and Py. aerophilum, fall within a range from 20 to 33% identity. A high level of conservation in and around the ligand-binding/active site is noted, with all of the residues implicated in the enzyme mechanism being strictly conserved (Fig. 4 [triangle]).
Figure 4
Figure 4
Primary and secondary structure of SaPurB together with sequence alignment of selected PurB sequences. Dark blue stars indicate residues that interact with ligands in the active site; a dark blue circle identifies a threonine previously thought to be (more ...)
The structure of AMP in the active site of SaPurB (Fig. 5 [triangle]) is similar to that in the E. coli PurB–AMP complex (Tsai et al., 2007 [triangle]; PDB code 2ptq). The AMP phosphate accepts hydrogen bonds from Arg4C, Tyr5C, Asn276C, Ser306A, Arg310A and via a water-mediated association with Arg326A. The ribose O2′ donates a hydrogen bond to the Arg67A carbonyl and O3′ accepts hydrogen bonds from the amide of Asp69A and Arg4C NH2. The glycosidic O4′ is 3.2 Å from Asp69A OD1, suggesting that the latter is protonated (data not shown). The adenine N1 accepts a hydrogen bond from Thr95A OG1; N6 donates hydrogen bonds to His141B NE2 and Gln212A OE1, residues which are themselves positioned by hydrogen-bonding interactions. The loop Gly182-Ala183-Val184-Gly185, which is conserved in PurB sequences (Fig. 4 [triangle]), is positioned such that the main-chain carbonyl of Ala183 can accept a hydrogen bond from Gln212A NE2. His141 in SaPurB corresponds to His171 in E. coli PurB and is the catalytic acid for the mechanism (Tsai et al., 2007 [triangle]; Kozlov et al., 2009 [triangle]).
Figure 5
Figure 5
Stereoview of the active site. A molecule of AMP is bound in the active site formed by regions of three of the four subunits. There are four active sites per tetramer, with each active site formed by contributions from three of the four subunits, in this (more ...)
The oxalate binds accepting hydrogen bonds donated from Ser94A OG and Gln259A NE2 and a water molecule that in turn interacts with the side chain of Thr95 (Fig. 2 [triangle]). The distance between an oxalate oxygen and Ser94 OG is 3.6 Å and this may indicate a hydrogen bond. In contrast, the oxalate is 3.4 Å distant from adenine N6 but the geometry is not optimal for hydrogen-bond formation (Leonard et al., 1995 [triangle]). The oxalate occupies a position similar to that observed for fumarate in the active site of human PurB (PDB code 2vd6) and to that of the succinate moiety observed in the E. coli PurB–adenylosuccinate complex (PDB code 2ptr).
A model of SaPurB with adenylosuccinate was produced (Fig. 6 [triangle]) using the human PurB complex to aid the analysis. Two threonines, Thr93 and Thr140 in SaPurB, are proposed to bind the succinyl moiety (Segall et al., 2007 [triangle]). In SaPurB, Thr93 is almost 8 Å distant from N6. There is a water-mediated link between Thr140 and Asn270 and the asparagine is the more likely residue to interact with the succinyl group. Gln212 is placed to interact with AMP N6 and a carbonyl on the modelled SAICAR–adenylosuccinate. In SaPurB, Gln259 binds the oxalate, is positioned on a loop that displays elevated thermal parameters (data not shown) and could undergo a small conformational change to interact with substrate/products.
Figure 6
Figure 6
Stereoview of the adenylosuccinate model in the active site of SaPurB. The colour scheme is the same as that used in Fig. 2 [triangle], except that the C atoms of the ligand are shown in light blue.
Two conserved residues, Ser94 and Ser306 in SaPurB (Figs. 4 [triangle] and 5 [triangle]), have previously attracted attention (Segall et al., 2007 [triangle]). Ser94 is close to His68 and might influence the pK to favour the protonated form. In SaPurB His68 ND1 accepts a hydrogen bond from the Val70 amide and thus NE2 would under normal conditions carry a proton. Our model suggests that Ser94, like Ser306, binds substrate. In SaPurB Asp69 orients Arg310 so that it can in turn bind the substrate phosphate.
One side of the SaPurB active site is formed by a mobile loop that links β5 and α12. The electron density for this loop is more diffuse than in other parts of the structure and the thermal parameters are higher (data not shown). In most other PurB structures this loop is completely disordered (Fig. 4 [triangle]). In E. coli PurB this loop is disordered in the apo structure but ligand binding induces a reorganization of the loop to close the ligand-binding site (Tsai et al., 2007 [triangle]).
PurB catalyzes a β-elimination that is thought to occur via a general acid–base uni–bi mechanism (Bridger & Cohen, 1968 [triangle]; Casey & Lowenstein, 1987 [triangle]). Previous studies identified His141, His68 and Ser262 as important residues (Lee et al., 1997 [triangle], 1998 [triangle], 1999 [triangle]; Tsai et al., 2007 [triangle]). The conserved Ser262 of SaPurB is positioned on the mobile loop near the active site and may abstract the Cβ proton of the substrate, helping to create a carbanion intermediate. His171 is the likely proton donor to N6 to support breakage of the C—N bond. The placement of the adenine in the SaPurB active site with respect to His141 suggests it is unlikely that protonation of N1 occurs during catalysis, which was a possibility presented by Tsai et al. (2007 [triangle]).
His141 has been suggested to be the catalytic base (Lee et al., 1997 [triangle]), forming a charge-relay pair with Glu275 to extract a proton from the substrate (Toth & Yeates, 2000 [triangle]) or alternatively Ser262 (Tsai et al., 2007 [triangle]; corresponding to Ser295 in E. coli). The latter assignment was made from structural information on the apo form of E. coli PurB, in which the side chain of His171 (His141 in SaPurB) was rotated away from the position expected for it to play a role in catalysis. In E. coli PurB structures the highly conserved Ser295 (Ser262 of SaPurB) is close to the site of catalysis. This is not the situation in SaPurB, where the conformation of the active-site loop holds Ser262 distant from the catalytic site (Fig. 7 [triangle]). Lys268 of SaPurB, a strictly conserved residue (Fig. 4 [triangle]), is positioned with its NZ atom 2.8 Å from a succinyl carbonyl. Mutagenesis of the equivalent lysine in B. subtilis PurB decreased the enzyme activity significantly (Brosius & Colman, 2002 [triangle]).
Figure 7
Figure 7
Stereoview of the different conformations displayed by the active-site loop. The SaPurB structure is shown in purple and the E. coli enzyme structure is shown in pink. The adenylosuccinate is depicted as in Fig. 6 [triangle].
Our model supports the idea that His9 of the E. coli enzyme, which is equivalent to SaPurB His68, is not the catalytic base but rather binds and orients the substrate to interact with fumarate (Tsai et al., 2007 [triangle]). In SaPurB the oxalate is 3.8 Å distant from His68, but our model (Fig. 6 [triangle]) suggests that the distance would be about 3 Å in the substrate complex.
3.4. Dimer interface and the potential for inhibitor development
We were intrigued by two observations. Firstly, a tetramer (or dimer of dimers) is required to produce a functional enzyme since three subunits are required to contribute residues to form an active site. Secondly, there is less sequence conservation amongst the PurB residues involved in the assembly of the quaternary structure than those around the active sites. We decided to consider the dimer interface as a potential target for screening and structure-based drug-discovery methods.
Targeting transient protein–protein interactions or the interface of oligomeric assemblies by screening and structure-based methods to find small-molecule drug-like inhibitors presents a significant challenge (Yin & Hamilton, 2005 [triangle]). Complicating factors include the high degree of specificity and the large areas of interactions involved in complex formation. Nevertheless, PurB exists in dimeric and tetrameric forms, with enzyme activity restricted to the tetrameric form. Therefore, preventing the formation of or destabilizing the tetramer provides a route to enzyme inhibition. Our interest was furthered by the observation that there is a marked reduction in sequence conservation amongst those residues involved in the assembly of the quaternary structure.
In support of such an approach, we note that in excess of 30 point mutations have been identified that cause human adenylosuccinate lyase deficiency, several of which influence the stability of the tetramer (Spiegel et al., 2006 [triangle]). For example, the mutation of Lys246 to glutamic acid in the human enzyme is located at the AB or CD subunit interface and results in a predominantly monomeric protein with negligible enzyme activity. In addition, the presence of an Arg194-to-cysteine mutation has been demonstrated to reduce the thermal stability of the B. subtilis enzyme tetramer, leading to significant impairment of catalytic activity (Ariyananda et al., 2009 [triangle]).
Visualization of the electrostatic properties of the dimer–dimer interface involved in tetramer formation for both the human and S. aureus enzymes was achieved using the Adaptive Poisson-Boltzman Solver (Baker et al., 2001 [triangle]; Fig. 8 [triangle]). In SaPurB two acidic pockets are formed ~13 Å from either end of the helical coil region formed by domain II of each monomer within the AB dimer. The identical view of the human enzyme reveals a less acidic and smaller pocket. The residues forming the surface of this pocket are contributed from α10, α12 and from the loop linking α12 to α13. The symmetry of the dimer leads to a second pocket being formed 15 Å away and when the symmetry of the tetramer is considered four such pockets are created which combine to form two cavities within the core of the tetramer of approximately 13 × 10 × 10 Å in size. As mentioned perviously, targeting interface regions to disrupt oligomerization presents a significant challenge to drug discovery but this region in SaPurB may be more attractive owing to the symmetry of the tetramer. The effect of a small molecule targeted to the pocket on the surface of one subunit could be amplified by the proximity of four such pockets, offering the potential to exploit multivalent ligands.
Figure 8
Figure 8
The dimer–dimer interface of (a) the human enzyme and (b) SaPurB. The protein is depicted as a van der Waals surface coloured blue for basic properties, red for acidic and grey for neutral. For reference, the position of α12 in SaPurB (more ...)
The SaPurB structure displays a conserved fold and mode of oligomerization compared with orthologous enzymes. The active sites are highly conserved between species and this extends to the presence of a flexible loop at the active site. The SaPurB structure contained AMP and a likely contaminant, oxalate, in the active site. The high degree of conservation in the PurB active sites would render it difficult to identify a potent species-specific inhibitor of value in the development of new therapeutic agents. In contrast, the dimer interface of PurB from S. aureus appears to be sufficiently distinct from that observed for the human orthologue that it may represent a potential target for which inhibitors might be developed. However, we note the not inconsiderable difficulties in adopting such an approach.
Supplementary Material
PDB reference: adenylo­succinate lyase, 2x75
Acknowledgments
This research was funded by the Scottish Funding Council, the Biotechnology and Biological Sciences Research Council (Structural Proteomics of Rational Targets, BBS/B/14434) and The Wellcome Trust (grant Nos. 082596 and 083481). We acknowledge the Diamond Light Source for synchrotron beam time and excellent staff support.
  • Ariyananda, L. D. Z., Lee, P., Antonopoulos, C. & Colman, R. (2009). Biochemistry, 48, 5291–5302. [PMC free article] [PubMed]
  • Baker, N. A., Sept, D., Joseph, S., Holst, M. J. & McCammon, J. A. (2001). Proc. Natl Acad. Sci. USA, 98, 10037–10041. [PubMed]
  • Bridger, W. A. & Cohen, L. H. (1968). J. Biol. Chem.243, 644–650. [PubMed]
  • Brosius, J. L. & Colman, R. F. (2002). Biochemistry, 41, 2217–2226. [PubMed]
  • Buchanan, J. M. & Hartman, S. C. (1959). Adv. Enzymol. Relat. Areas Mol. Biol.21, 199–261.
  • Casey, P. J. & Lowenstein, J. M. (1987). Biochem. J.246, 263–269. [PubMed]
  • Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S. & Richardson, D. C. (2010). Acta Cryst. D66, 12–21. [PMC free article] [PubMed]
  • Dawson, A., Fyfe, P. K. & Hunter, W. N. (2008). J. Mol. Biol.384, 1353–1368. [PMC free article] [PubMed]
  • DeLano, W. L. (2002). The PyMOL Molecular Viewer. http://www.pymol.org.
  • Edgar, R. C. (2004). Nucleic Acids Res.32, 1792–1797. [PMC free article] [PubMed]
  • Emsley, P. & Cowtan, K. (2004). Acta Cryst. D60, 2126–2132. [PubMed]
  • Evans, P. (2006). Acta Cryst. D62, 72–82. [PubMed]
  • Fujii, T., Sakai, H., Kawata, Y. & Hata, Y. (2003). J. Mol. Biol.328, 635–654. [PubMed]
  • Gasteiger, E., Hoogland, C., Gattiker, A., Duvaud, S., Wilkins, M. R., Appel, R. D. & Bairoch, A. (2005). The Proteomics Protocols Handbook, edited by J. M. Walker, pp. 571–607. Totowa: Humana Press.
  • Heinemann, M., Kümmel, A., Ruinatscha, R. & Panke, S. (2005). Biotechnol. Bioeng.92, 850–864. [PubMed]
  • Hunter, W. N. (2009). J. Biol. Chem.284, 11749–11753. [PMC free article] [PubMed]
  • Jurnak, F. (1986). J. Cryst. Growth, 76, 578–582.
  • Kozlov, G., Nguyen, L., Pearsall, J. & Gehring, K. (2009). Acta Cryst. F65, 857–861. [PMC free article] [PubMed]
  • Krissinel, E. & Henrick, K. (2007). J. Mol. Biol.372, 774–797. [PubMed]
  • Lee, T. T., Worby, C., Bao, Z.-Q., Dixon, J. E. & Colman, R. F. (1998). Biochemistry, 37, 8481–8489. [PubMed]
  • Lee, T. T., Worby, C., Bao, Z.-Q., Dixon, J. E. & Colman, R. F. (1999). Biochemistry, 38, 22–32. [PubMed]
  • Lee, T. T., Worby, C., Dixon, J. E. & Colman, R. F. (1997). J. Biol. Chem.272, 458–465. [PubMed]
  • Leonard, G. A., McAuley-Hecht, K., Brown, T. & Hunter, W. N. (1995). Acta Cryst. D51, 136–139. [PubMed]
  • Leslie, A. G. W. (2006). Acta Cryst. D62, 48–57. [PubMed]
  • McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J. (2007). J. Appl. Cryst.40, 658–674. [PMC free article] [PubMed]
  • Mueller, E. J., Meyer, E., Rudolph, J., Davisson, V. J. & Stubbe, J. (1994). Biochemistry, 33, 2269–2278. [PubMed]
  • Murshudov, G. N., Vagin, A. A., Lebedev, A., Wilson, K. S. & Dodson, E. J. (1999). Acta Cryst. D55, 247–255. [PubMed]
  • Palenchar, J. B. & Colman, R. F. (2003). Biochemistry, 42, 1831–1841. [PubMed]
  • Ray, W. J. & Puvathingal, J. M. (1985). Anal. Biochem.146, 307–312. [PubMed]
  • Segall, M. L., Cashman, M. A. & Colman, R. F. (2007). Protein Sci.16, 441–448. [PubMed]
  • Spiegel, E. K., Colman, R. F. & Patterson, D. (2006). Mol. Gen. Metabol.89, 19–31. [PubMed]
  • Toth, E. A., Worby, C., Dixon, J. E., Goedken, E. R., Marqusee, S. & Yeates, T. O. (2000). J. Mol. Biol.301, 433–450. [PubMed]
  • Toth, E. A. & Yeates, T. O. (2000). Structure, 8, 163–174. [PubMed]
  • Tsai, M., Koo, J., Yip, P., Colman, R. F., Segall, M. L. & Howell, P. L. (2007). J. Mol. Biol.370, 541–554. [PubMed]
  • Vedadi, M. et al. (2007). Mol. Biochem. Parasitol.151, 100–110. [PubMed]
  • Yin, H. & Hamilton, A. D. (2005). Angew. Chem. Int. Ed. Engl.44, 4130–4163. [PubMed]
  • Zhang, Y., Morar, M. & Ealick, S. E. (2008). Cell. Mol. Life Sci.65, 3699–3724. [PMC free article] [PubMed]
Articles from Acta Crystallographica Section D: Biological Crystallography are provided here courtesy of
International Union of Crystallography